Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients

Inclusion Criteria: * 18 to 75 years old * Stage II or III colorectal cancer patients confirmed by pathological diagnosis, and recovered from surgery within 8 weeks * should receive adjuvant chemotherapy especially XELOX regimen after assessment by physicians and specialists * Agreed and assigned the consent, and was able to receive the baseline assessment * Could be inpatient or outpatient participants Exclusion Criteria: * Peripheral neuropathy patients, e.g. diabetes neuropathy * Alcoholic related patients * Central neuropathy patients * Patients who were unable to assess the effectivity and safety * Neurotropin allergy * History of medications that are contraindicated to neurotropin \<28 days before the trial begins * Have already received neurotropin tablets more than 4 tablets or 3.6 units \<4 weeks before the trials begins * Unable to visit the hospital regularly * Has been ruled out by investigators * Brain tumor or metastasis * Brain injury, stroke and brain hemorrhage symptoms occurred during 6 months after sign the consent * History of epilepsy, convulsion * Severe respiratory, cardiovascular, renal, hepatic or hematologic system(except cancer) disease * Depression and other psychologic conditions which investigators recognized as high risk for the enrollment * Chronic pain * Received other medication from other clinical trials within 28 days * Prepare for pregnancy, pregnant, or lactated women